Patents Assigned to KINASE PHARMA INC.
  • Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases
    Patent number: 11793889
    Abstract: The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for selectively inhibiting one or more kinases in one or more tissues. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject where the selective inhibition of kinases with endogenously produced antagonists of kinases may be useful in treating conditions such as cancer, autoimmune disease, and transplant rejection.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: October 24, 2023
    Assignee: Kinase Pharma Inc.
    Inventor: Bradley G Thompson
  • Compositions and method of making a complex able to increase production of a cetuximab-like protein (CLP) in a target cell
    Patent number: 11603541
    Abstract: The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a Cetuximab-like protein (CLP) by a subject that is administered the agent, therapy or treatment. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition that may benefit from reducing the DNA synthesis of genes that regulate cellular growth and proliferation.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: March 14, 2023
    Assignee: KINASE PHARMA INC.
    Inventor: Bradley G. Thompson